康诺亚 TSLP 单抗启动新 III 期，石药拥有权益_老虎社区_美港股上老虎

康诺亚 TSLP 单抗启动新 III 期，石药拥有权益

丁香园 Insight 数据库02-05

药物临床试验登记与信息公示平台官网显示，康诺亚登记了一项评价 CM326 重组人源化单克隆抗体注射液治疗慢性鼻窦炎伴鼻息肉患者的有效性、安全性的多中心、随机、双盲、安慰剂平行对照的 III 期临床试验（登记号：CTR20260394）。来源：药物临床试验登记与信息公示平台官网该研究计划纳入212 名受试者，随机分组接受 CM326 和安慰剂治疗，每 4 周给药一次，双盲治疗期内共给药 6 次，开放...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

暂无评论

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2609133589?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-02-05 17:12","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2609133589","market":"hk","top_or_hot":-1,"title":"康诺亚 TSLP 单抗启动新 III 期，石药拥有权益","media":"丁香园 Insight 数据库","content":"<div>\n<p>药物临床试验登记与信息公示平台官网显示，康诺亚登记了一项评价 CM326 重组人源化单克隆抗体注射液治疗慢性鼻窦炎伴鼻息肉患者的有效性、安全性的多中心、随机、双盲、安慰剂平行对照的 III 期临床试验（登记号：CTR20260394）。来源：药物临床试验登记与信息公示平台官网该研究计划纳入212 名受试者，随机分组接受 CM326 和安慰剂治疗，每 4 周给药一次，双盲治疗期内共给药 6 次，开放...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020519483897a50562&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>康诺亚 TSLP 单抗启动新 III 期，石药拥有权益</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n康诺亚 TSLP 单抗启动新 III 期，石药拥有权益\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-05 17:12 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020519483897a50562&s=b><strong>丁香园 Insight 数据库</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>药物临床试验登记与信息公示平台官网显示，康诺亚登记了一项评价 CM326 重组人源化单克隆抗体注射液治疗慢性鼻窦炎伴鼻息肉患者的有效性、安全性的多中心、随机、双盲、安慰剂平行对照的 III 期临床试验（登记号：CTR20260394）。来源：药物临床试验登记与信息公示平台官网该研究计划纳入212 名受试者，随机分组接受 CM326 和安慰剂治疗，每 4 周给药一次，双盲治疗期内共给药 6 次，开放...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020519483897a50562&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B543WZ88.USD","symbol_name":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020519483897a50562&s=b","article_id":"2609133589","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020519483897a50562&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2609133589","pubTimestamp":1770282749,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"TSLP 是炎症级联反应的启动因子之一，抑制 TSLP 可以从炎症发生的早期进行干预，阻止免疫细胞释放促炎细胞因子。其中哮喘已经推进至 III 期临床研究。2021 年 11 月，康诺亚与石药集团达成合作，将 CM326 在中重度哮喘和慢性阻塞性肺病等呼吸系统疾病开发及商业化权益独家授予后者。2024 年 11 月，康诺亚同意扩大授予石药集团的特许权使用领域至所有适应症。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","IE00B031HY20.USD":"FSSA CHINA GROWTH \"I\" (USD) INC","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","LU1226287529.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) ACC","LU1226288170.HKD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P6%\"(HK D) INC","LU1226287875.USD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"PM\" (USD) INC","LU0880133367.SGD":"UBS (LUX) EQUITY FUND CHINA OPPORTUNITY USD \"P\" (SGD) ACC","BK1515":"抗疫概念","BK1587":"次新股","LU1226288253.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) INC","BK1574":"生物医药B类股","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","LU2039709279.SGD":"MANULIFE GF DRAGON GROWTH \"AA\" (SGDHDG) INC","LU1951186391.HKD":"UBS (LUX) KEY SEL CHINA ALLOCATION OPPORTUNITY (US \"P\" (HKD) INC","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","BK1583":"高瓴概念","IE0008369823.USD":"FSSA HONG KONG GROWTH \"I\" ACC","LU1813983027.USD":"MANULIFE GF DRAGON GROWTH \"AA\" (USD) INC","01093":"石药集团","LU0072913022.USD":"UBS (LUX) EQUITY FUND -  GREATER CHINA \"P\" (USD) ACC","LU1152091168.USD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" INC","BK1521":"挪威政府全球养老基金持仓","LU1993786604.SGD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (SGD) ACC","LU1807302812.USD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (USD) ACC","LU1008478684.HKD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (HKD) ACC","LU1226287792.SGD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P\" (SGDHDG) INC","LU1960683339.HKD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (HKD) ACC","LU0140636845.USD":"施罗德大中华区股票A Acc","IE00BZ08YR35.GBP":"GUINNESS BEST OF CHINA \"C\" (GBP) ACC","LU0067412154.USD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (USD) ACC","LU0501845795.SGD":"瑞银大中华区股票基金P Acc SGD","BK1191":"制药","LU0315179316.USD":"EASTSPRING INVESTMENTS ASIAN DYNAMIC \"A\" (USD) ACC","IE00BZ08YS42.EUR":"GUINNESS BEST OF CHINA \"C\" (EUR) ACC","LU1328277881.USD":"MANULIFE GF DRAGON GROWTH FUND \"AA\" (USD) INC","IE00BZ08YT58.USD":"GUINNESS BEST OF CHINA \"C\" (USD) ACC","LU1152091754.HKD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" (HKD) INC","SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","02162":"康诺亚-B","LU0314109678.HKD":"MANULIFE GF DRAGON GROWTH \"AA\" (HKD) INC","IE0008368742.USD":"首域中国增长基金I Acc","BK1161":"生物科技"},"translate_title":"Connuoya TSLP monoclonal antibody launches new phase III, CSPC owns interest","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02162":1.5,"01093":1.5},"content_text":"药物临床试验登记与信息公示平台官网显示，康诺亚登记了一项评价 CM326 重组人源化单克隆抗体注射液治疗慢性鼻窦炎伴鼻息肉患者的有效性、安全性的多中心、随机、双盲、安慰剂平行对照的 III 期临床试验（登记号：CTR20260394）。来源：药物临床试验登记与信息公示平台官网该研究计划纳入212 名受试者，随机分组接受 CM326 和安慰剂治疗，每 4 周给药一次，双盲治疗期内共给药 6 次，开放标签治疗期内共给药 7 次。主要终点是治疗第 24 周时，鼻息肉评分（NPS）较基线的变化，以及鼻塞评分（NCS）较基线的变化。CM326 是由康诺亚研发的具有全新作用机制的 1 类创新药，靶向胸腺基质淋巴细胞生成素（TSLP）。TSLP 是炎症级联反应的启动因子之一，抑制 TSLP 可以从炎症发生的早期进行干预，阻止免疫细胞释放促炎细胞因子。目前，CM326 正在开展多项临床研究，适应症包括哮喘、慢性鼻窦炎伴鼻息肉病、特应性皮炎和慢性阻塞性肺病。其中哮喘已经推进至 III 期临床研究。2021 年 11 月，康诺亚与石药集团达成合作，将 CM326 在中重度哮喘和慢性阻塞性肺病等呼吸系统疾病开发及商业化权益独家授予后者。2024 年 11 月，康诺亚同意扩大授予石药集团的特许权使用领域至所有适应症。封面来源：企业logo","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}